ACTIVE

ARQUENNES PHARMA

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

132,4 k €

+8.7% YoY

Gross margin

462,1 k €

-4.4% YoY

Equity

238,4 k €

+1.0% YoY

Workforce

4,0 ETP

-7.0% YoY

What does ARQUENNES PHARMA do?

ARQUENNES PHARMA is a Public limited company incorporated in 1991. Its registered office is in Seneffe. It employs on average 4,0 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0442.964.356

Incorporation

07/01/1991

Legal form

Public limited company

Registered office

Chaussée de Nivelles 141 box 2
7181 Seneffe · WallonieSee on map

Contributed capital

62 000,00 €

Latest accounts

31/12/2025

Average workforce

4,0 ETP

Joint committees (2)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 20 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	462,1 k €	-4.4%	483,1 k €	+13.0%	427,5 k €	+7.7%	396,9 k €	+4.1%	381,4 k €	+14.3%	333,7 k €	+7.4%	310,7 k €	-5.3%	327,9 k €	+19.0%	275,6 k €	-20.1%	345 k €	+12.0%	307,9 k €	+39.5%	220,8 k €	+63.2%	135,3 k €	+5.9%	127,7 k €	-3.3%	132,1 k €	-0.6%	133 k €	+5.4%	126,1 k €	+20.3%	104,8 k €	+12.4%	93,3 k €	+37.7%	67,7 k €
EBITDA	170,5 k €	-7.7%	184,7 k €	+39.4%	132,5 k €	-17.3%	160,3 k €	-1.7%	163 k €	+19.7%	136,2 k €	+29.5%	105,1 k €	-29.2%	148,4 k €	+29.7%	114,4 k €	-47.1%	216,5 k €	+34.3%	161,3 k €	+34.4%	120 k €	+88.4%	63,7 k €	+10.6%	57,6 k €	-18.1%	70,3 k €	+17.8%	59,7 k €	+25.2%	47,7 k €	+65.2%	28,9 k €	+41.5%	20,4 k €	+809%	-2,9 k €
Operating result	157,9 k €	+4.0%	151,8 k €	+121%	68,6 k €	-22.0%	88 k €	-2.8%	90,6 k €	+38.7%	65,3 k €	+85.8%	35,2 k €	-53.8%	76 k €	+79.5%	42,4 k €	-68.9%	136,2 k €	+91.8%	71 k €	+85.8%	38,2 k €	+20.6%	31,7 k €	-3.7%	32,9 k €	-27.6%	45,4 k €	+2.9%	44,2 k €	+42.7%	30,9 k €	+486%	5,3 k €	-61.6%	13,8 k €	+230%	-10,6 k €
Net result	132,4 k €	+8.7%	121,8 k €	+180%	43,5 k €	-35.4%	67,4 k €	-2.6%	69,2 k €	+54.7%	44,8 k €	+289%	11,5 k €	-77.2%	50,4 k €	+210%	16,3 k €	-82.4%	92,5 k €	+110%	44,1 k €	+5623%	770,4 €	+13.6%	678,4 €	-90.5%	7,1 k €	-55.0%	15,8 k €	-19.7%	19,7 k €	+101%	9,8 k €	+884%	-1,3 k €	-110%	12,6 k €	+195%	-13,2 k €
Balance sheet
Equity	238,4 k €	+1.0%	236 k €	+0.8%	234,2 k €	+1.5%	230,7 k €	+1.1%	228,3 k €	+0.5%	227,1 k €	+0.3%	226,3 k €	+0.9%	224,3 k €	+0.2%	223,9 k €	+0.6%	222,6 k €	+25.0%	178,1 k €	+2.4%	174 k €	+0.4%	173,3 k €	+0.4%	172,6 k €	+4.3%	165,5 k €	+10.6%	149,7 k €	+15.1%	130 k €	+8.2%	120,2 k €	-1.0%	121,4 k €	+11.5%	108,9 k €
Total assets	712,6 k €	-12.0%	809,6 k €	+9.2%	741,5 k €	-4.4%	776 k €	-6.2%	827 k €	-9.5%	913,6 k €	+1.1%	904 k €	-9.6%	1 M €	-6.6%	1,1 M €	-8.0%	1,2 M €	+4.8%	1,1 M €	-16.2%	1,3 M €	+80.4%	734,3 k €	+4.4%	703,2 k €	+2.3%	687,7 k €	+14.0%	603,3 k €	+4.7%	576,3 k €	+1.7%	566,5 k €	+244%	164,5 k €	+0.6%	163,6 k €
Cash	197,2 k €	-9.2%	217,2 k €	+42.4%	152,5 k €	-5.8%	161,8 k €	-6.4%	172,9 k €	+23.7%	139,7 k €	+40.6%	99,4 k €	-12.7%	113,9 k €	-18.7%	140,1 k €	-16.1%	167 k €	+609%	23,5 k €	-76.1%	98,4 k €	-24.3%	130 k €	-16.1%	154,9 k €	+46.9%	105,4 k €	+54.1%	68,4 k €	+83.0%	37,4 k €	-14.1%	43,5 k €	+90.7%	22,8 k €	-34.9%	35 k €
Debts	474,2 k €	-14.6%	555,4 k €	+12.3%	494,7 k €	-7.9%	537 k €	-6.4%	573,8 k €	-14.3%	670 k €	+0.1%	669,4 k €	-12.8%	767,7 k €	-8.7%	840,8 k €	-9.7%	931,3 k €	+0.9%	923 k €	-19.0%	1,1 M €	+106%	553,4 k €	+4.3%	530,5 k €	+1.6%	522,1 k €	+15.1%	453,4 k €	+1.6%	446,1 k €	+0.2%	445,3 k €	+933%	43,1 k €	-21.3%	54,7 k €
Other
Workforce	4,0 ETP	-7.0%	4,3 ETP	+2.4%	4,2 ETP	0.0%	4,2 ETP	+10.5%	3,8 ETP	-5.0%	4,0 ETP	+2.6%	3,9 ETP	0.0%	3,9 ETP	+39.3%	2,8 ETP	-15.2%	3,3 ETP	+37.5%	2,4 ETP	+26.3%	1,9 ETP	+26.7%	1,5 ETP	-21.1%	1,9 ETP	-9.5%	2,1 ETP	+10.5%	1,9 ETP	-13.6%	2,2 ETP	-15.4%	2,6 ETP	0.0%	2,6 ETP	0.0%	2,6 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2025 · 4 active · 11 ended

Active mandates

Anne DEJARDIN

Managing director

Active

EGUIMAX INVEST

Director · 0667.584.187

Represented by Philippe Dehaye

Active

GFCS INVEST

Director · 0667.583.296

Represented by ALEXANDRE DEHAYE

Active

Nadine DEMEULEMEESTER

Director

Active

Ended mandates

Alexandre DEHAYE

Director

Ended

Anne Dejardin

Director

Ended

Anne DUJARDIN

Managing director

Ended

Annee DEJARDIN

Managing director

Ended

At this address

Other companies at this address

Company	CBE no.
TENAGLIA MATHILDE● Active	1029.817.722

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	31/08/2026	22/08/2025	29/08/2024	29/08/2023	27/07/2022	31/08/2021
General meeting	11/06/2026	12/06/2025	13/06/2024	08/06/2023	09/06/2022	10/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

20 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	11/06/2026	31/08/2026	French	PDF
Abridged model	31/12/2024	12/06/2025	22/08/2025	French	PDF
Abridged model	31/12/2023	13/06/2024	29/08/2024	French	PDF
Abridged model	31/12/2022	08/06/2023	29/08/2023	French	PDF
Abridged model	31/12/2021	09/06/2022	27/07/2022	French	PDF
Abridged model	31/12/2020	10/06/2021	31/08/2021	French	PDF
Abridged model	31/12/2019	11/06/2020	28/10/2020	French	PDF
Abridged model	31/12/2018	13/06/2019	30/07/2019	French	PDF
Abridged model	31/12/2017	14/06/2018	31/07/2018	French	PDF
Abridged model	31/12/2016	08/06/2017	11/07/2017	French	PDF
Abridged model	31/12/2015	09/06/2016	31/08/2016	French	PDF
Abridged model	31/12/2014	11/06/2015	14/08/2015	French	PDF
Abridged model	31/12/2013	03/07/2014	31/07/2014	French	PDF
Abridged model	31/12/2012	13/06/2013	29/07/2013	French	PDF
Abridged model	31/12/2011	05/07/2012	31/07/2012	French	PDF
Abridged model	31/12/2010	09/06/2011	27/07/2011	French	PDF
Abridged model	31/12/2009	10/06/2010	05/07/2010	French	PDF
Abridged model	31/12/2008	11/06/2009	30/10/2009	French	PDF
Abridged model	31/12/2007	12/06/2008	16/06/2008	French	PDF
Abridged model	31/12/2006	14/06/2007	17/07/2007	French	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 4 active · 11 ended

Active mandates

Anne DEJARDIN

Managing director

Active

EGUIMAX INVEST

Director · 0667.584.187

Represented by Philippe Dehaye

Active

GFCS INVEST

Director · 0667.583.296

Represented by ALEXANDRE DEHAYE

Active

Nadine DEMEULEMEESTER

Director

Active

Ended mandates

Alexandre DEHAYE

Director

Ended

Anne Dejardin

Director

Ended

Anne DUJARDIN

Managing director

Ended

Annee DEJARDIN

Managing director

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates18/08/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates09/01/2024
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - DEMISSIONS, NOMINATIONS
PDF
Mandates02/01/2017
DEMISSIONS, NOMINATIONS
PDF
Mandates20/02/2015
DEMISSIONS, NOMINATIONS
PDF
Registered office24/03/2014
SIEGE SOCIAL
PDF
Mandates29/03/2012
DENOMINATION - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Mandates18/11/2008
DEMISSIONS, NOMINATIONS
PDF
Mandates09/07/2008
DEMISSIONS, NOMINATIONS
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2025
Annual accounts 2025132,4 k €↑
2024
Annual accounts 2024121,8 k €↑
2023
Annual accounts 202343,5 k €↓
2022
Annual accounts 202267,4 k €↓
2021
Annual accounts 202169,2 k €↑
2020
Annual accounts 202044,8 k €↑
2019
Annual accounts 201911,5 k €↓
2018
Annual accounts 201850,4 k €↑
2017
Annual accounts 201716,3 k €↓
2016
Annual accounts 201692,5 k €↑
2015
Annual accounts 201544,1 k €↑
2014
Annual accounts 2014770,4 €↑
2013
Annual accounts 2013678,4 €↓
2012
Annual accounts 20127,1 k €↓
2011
Annual accounts 201115,8 k €↓
2010
Annual accounts 201019,7 k €↑
2009
Annual accounts 20099,8 k €↑
2008
Annual accounts 2008-1,3 k €↓
2007
Annual accounts 200712,6 k €↑
2006
Annual accounts 2006-13,2 k €
07/01/1991
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

ARQUENNES PHARMA

Overview

What does ARQUENNES PHARMA do?

Trend over 20 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline